The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

Phase 1 Completed 13 enrolled BeiGene

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study was to determine the effect of the moderate cytochrome P450 3A (CYP3A) inducer rifabutin on the pharmacokinetics (PK) of zanubrutinib in healthy males.

Timeline

Start: 2020-07-29
Primary completion: 2020-11-10
Completion: 2020-11-10

Publications

Tariq B, Conto S, Cohen A, Sahasranaman S, Ou YC. A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers. Clin Pharmacol Drug Dev. 2023 Aug;12(8):832-838. doi: 10.1002/cpdd.1250. Epub 2023 May 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rifabutin	Small molecule	300 mg	Oral
Subject	Zanubrutinib	Small molecule	320 mg	Oral

Indications

No indication recorded.